D-0555-2026 Class II Ongoing

Recalled by Asclemed USA Inc. — Torrance, CA

FDA drug recall D-0555-2026 was initiated by Asclemed USA Inc. on May 14, 2026 and is designated Class II. Reason for recall: CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit. The recall status is ongoing. Affected quantity: 50 bottles.

Recall details

Product Type
Drugs
Report Date
Jun 10, 2026
Initiation Date
May 14, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
50 bottles

Product description

Duloxetine DR Capsules, 30 mg, 30 count bottles, Rx, Relabeled by: Enovachem Pharmaceuticals, Torrance, CA 90501, NDC 76420-634-30, Marketed by: Ajanta Pharma USA Inc.

Reason for recall

CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.

Distribution pattern

US Nationwide.

Code information

Lot # 050725G-30 & 050725F-30, Exp Date: 06/30/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0555-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0555-2026. Report a data issue: hello@regdatalab.com.